Article History
Received: 14 July 2020
Revised: 22 September 2020
Accepted: 24 September 2020
First Online: 9 October 2020
Conflict of interest
: A.D.S. has received honorariums or consulting fees from Novartis, Jazz, Otsuka, and Takeda Pharmaceuticals and research support from Medivir AB and Takeda. A.D.S. owns stock in Abbvie Pharmaceuticals and is named on a patent application for the use of DNT cells for the treatment of leukemia.